| Scrip Code | 507747 |
|---|---|
| NSE Symbol | TTKHLTCARE |
| MSEI Symbol | NOTLISTED |
| ISIN | INE910C01018 |
| Name of company | TTK HEALTHCARE LIMITED |
| Type of company | Main Board |
| Class of security | Equity |
| Date of start of financial year | 01-04-2026 |
| Date of end of financial year | 31-03-2027 |
| Date of board meeting when results were approved | 06-08-2026 |
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 27-07-2026 |
| Description of presentation currency | INR |
| Level of rounding used in financial results | Lakhs |
| Reporting Type | Quarterly |
| Reporting Quarter | First quarter |
| Nature of report standalone or consolidated | Standalone |
| Whether results are audited or unaudited for the quarter ended | Unaudited |
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |
| Segment Reporting | Multi segment |
| Description of single segment | |
| Start date and time of board meeting | 06-08-2026 12:00:00 |
| End date and time of board meeting | 06-08-2026 13:00:00 |
| Whether cash flow statement is applicable on company | |
| Type of cash flow statement | |
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable |
| Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? | No |
| No. of times funds raised during the quarter | |
| Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? | No |
| Not Applicable | |
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| 1 | Income | ||
| Revenue from operations | 25,755.76 | 25,755.76 | |
| Other income | 1,679.47 | 1,679.47 | |
| Total income | 27,435.23 | 27,435.23 | |
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 6,123.25 | 6,123.25 |
| (b) | Purchases of stock-in-trade | 5,513.27 | 5,513.27 |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (217.34) | (217.34) |
| (d) | Employee benefit expense | 4,661.27 | 4,661.27 |
| (e) | Finance costs | 53.12 | 53.12 |
| (f) | Depreciation, depletion and amortisation expense | 214.05 | 214.05 |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 8,201.78 | 8,201.78 |
| Total other expenses | 8,201.78 | 8,201.78 | |
| Total expenses | 24,549.40 | 24,549.40 | |
| 3 | Total profit before exceptional items and tax | 2,885.83 | 2,885.83 |
| 4 | Exceptional items | 0.00 | 0.00 |
| 5 | Total profit before tax | 2,885.83 | 2,885.83 |
| 6 | Tax expense | ||
| 7 | Current tax | 760.00 | 760.00 |
| 8 | Deferred tax | (2.09) | (2.09) |
| 9 | Total tax expenses | 757.91 | 757.91 |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0.00 | 0.00 |
| 11 | Net Profit Loss for the period from continuing operations | 2,127.92 | 2,127.92 |
| 12 | Profit (loss) from discontinued operations before tax | 0.00 | 0.00 |
| 13 | Tax expense of discontinued operations | 0.00 | 0.00 |
| 14 | Net profit (loss) from discontinued operation after tax | 0.00 | 0.00 |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0.00 | 0.00 |
| 16 | Total profit (loss) for period | 2,127.92 | 2,127.92 |
| 17 | Other comprehensive income net of taxes | 335.23 | 335.23 |
| 18 | Total Comprehensive Income for the period | 2,463.15 | 2,463.15 |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 1,413.03 | 1,413.03 | |
| Face value of equity share capital | 10 | 10 | |
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 15.06 | 15.06 | |
| Diluted earnings (loss) per share from continuing operations | 15.06 | 15.06 | |
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | 0 | |
| Diluted earnings (loss) per share from discontinued operations | 0 | 0 | |
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 15.06 | 15.06 | |
| Diluted earnings (loss) per share from continuing and discontinued operations | 15.06 | 15.06 | |
| 24 | Debt equity ratio | ||
| 25 | Debt service coverage ratio | ||
| 26 | Interest service coverage ratio | ||
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
| Textual Information(1) | Notes: (1) The above financial results for the First Quarter ended June 30, 2026 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 06, 2026 at the Registered Office of the Company, also with the provision of Video Conferencing facility. (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (3) During the Fourth Quarter of FY 2024-25, the Company had written off the entire value of Male Contraceptives pertaining to Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders. This write off was shown as Exceptional Item during FY 2024-25. In the First Quarter of this financial year, the Company has received orders for inventory amounting to Rs.544.63 lakhs, which were written off in FY 2024-25. Out of the order for Rs.544.63 lakhs, the Company has invoiced in First Quarter of this year, inventory amounting to Rs.509.92 lakhs for a selling value of Rs.701.85 lakhs to USAID, which is included in the revenue for the quarter. (4) Exceptional Items pertaining to the previous year: (a) On November 21, 2025, the Government of India notified the four Labour Codes, consolidating 29 existing labour laws, and the Ministry of Labour & Employment subsequently issued draft Central Rules and FAQs. Based on the best information available and in line with the guidance issued by the Institute of Chartered Accountants of India, the Company had assessed the incremental impact arising from the change in the definition of wages and, considering its material, regulatory-driven and non-recurring nature, had presented the same as Exceptional items in the Statement of Profit and Loss for the previous year ended March 31, 2026. The incremental impact comprised Gratuity of Rs.823.02 lakhs and Long-term Compensated Absences of Rs.284.85 lakhs, against which the provision of Rs.350 lakhs created in FY 2020–21 was adjusted, resulting in a net charge of Rs.757.87 lakhs being recognised in the previous financial year. (b) The Company had recognised Rs.350.42 lakhs as Exceptional Income during the previous financial year towards GST refund relating to earlier periods, which was received subsequently. (5) The Company has entered into definitive agreements with M/s. Wipro Enterprises Private Limited on July 23, 2026, for the sale of EVA and Good Home Brands and related assets, for a consideration of Rs.256 crores plus applicable GST, pursuant to approval by the Board of Directors on that date. The net book value of the related assets was Rs.70.48 lakhs as at June 30, 2026. Since the said transaction is expected to be completed by September 30, 2026, the impact of the same shall be given effect to in the Quarter in which it is completed. (6) The tax relating to earlier years mentioned in the previous year represents the tax refund relating to AY 2016-17 & AY 2017-18 received, consequent to completion of assessments. (7) The Company does not have any Subsidiary / Associate / Joint Venture Company(ies) as on June 30, 2026. (8) The figures for the Quarter ended March 31, 2026 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to Limited Review. (9) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation. (10) The full financial results for the First Quarter ended June 30, 2026 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com). |
|---|
| Debt equity ratio | |
|---|---|
| Debt service coverage ratio | |
| Interest service coverage ratio |
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
|---|---|---|---|---|---|---|---|
| Date of start of reporting period | 01-04-2026 | 01-04-2026 | |||||
| Date of end of reporting period | 30-06-2026 | 30-06-2026 | |||||
| Whether results are audited or unaudited | Unaudited | Unaudited | |||||
| Nature of report standalone or consolidated | Standalone | Standalone | |||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Animal Welfare | 3,589.50 | 3,589.50 | ||||
| 2 | Consumer Products | 7,703.46 | 7,703.46 | ||||
| 3 | Medical Devices | 3,359.33 | 3,359.33 | ||||
| 4 | Protective Devices | 7,269.06 | 7,269.06 | ||||
| 5 | Foods | 3,822.22 | 3,822.22 | ||||
| 6 | Others | 0.0001219 | 0.0001219 | ||||
| Total Segment Revenue | 25,755.76 | 25,755.76 | |||||
| Less: Inter segment revenue | 0.00 | 0.00 | |||||
| Revenue from operations | 25,755.76 | 25,755.76 | |||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Animal Welfare | 115.13 | 115.13 | ||||
| 2 | Consumer Products | 284.44 | 284.44 | ||||
| 3 | Medical Devices | 758.02 | 758.02 | ||||
| 4 | Protective Devices | 613.20 | 613.20 | ||||
| 5 | Foods | 412.32 | 412.32 | ||||
| 6 | Others | 10.84 | 10.84 | ||||
| Total Profit before tax | 2,193.95 | 2,193.95 | |||||
| i. Finance cost | 53.12 | 53.12 | |||||
| ii. Other Unallocable Expenditure net off Unallocable income | (745.00) | (745.00) | |||||
| Profit before tax | 2,885.83 | 2,885.83 | |||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Animal Welfare | 4,408.98 | 4,408.98 | ||||
| 2 | Consumer Products | 5,638.83 | 5,638.83 | ||||
| 3 | Medical Devices | 9,401.23 | 9,401.23 | ||||
| 4 | Protective Devices | 16,053.63 | 16,053.63 | ||||
| 5 | Foods | 5,564.48 | 5,564.48 | ||||
| 6 | Others | 303.01 | 303.01 | ||||
| Total Segment Asset | 41,370.16 | 41,370.16 | |||||
| Un-allocable Assets | 97,622.68 | 97,622.68 | |||||
| Net Segment Asset | 1,38,992.84 | 1,38,992.84 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Animal Welfare | 3,115.00 | 3,115.00 | ||||
| 2 | Consumer Products | 6,837.60 | 6,837.60 | ||||
| 3 | Medical Devices | 1,903.20 | 1,903.20 | ||||
| 4 | Protective Devices | 4,980.05 | 4,980.05 | ||||
| 5 | Foods | 1,577.73 | 1,577.73 | ||||
| 6 | Others | 134.64 | 134.64 | ||||
| Total Segment Liabilities | 18,548.22 | 18,548.22 | |||||
| Un-allocable Liabilities | 6,496.44 | 6,496.44 | |||||
| Net Segment Liabilities | 25,044.66 | 25,044.66 | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
| Textual Information(2) | Notes: (1) Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management. (2) Details of products included in each of the Segments are as below : (i) Animal Welfare comprise products for Veterinary use. (ii) Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home Range of Scrubbers, Air Fresheners, etc. (iii) Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc. (iv) Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products. (v) Foods comprise manufacturing and marketing of Food Products. v Others include Printing and Publishing of Maps and Atlases. (3) The Segment wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment. (4) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation. |
|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
|---|---|---|---|
| A | Date of start of reporting period | 01-04-2026 | 01-04-2026 |
| B | Date of end of reporting period | 30-06-2026 | 30-06-2026 |
| C | Whether results are audited or unaudited | Unaudited | Unaudited |
| D | Nature of report standalone or consolidated | Standalone | Standalone |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Items that will not be reclassified subsequently to profit or loss | 345.99 | 345.99 |
| Total Amount of items that will not be reclassified to profit and loss | 345.99 | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 10.76 | 10.76 |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| Total Amount of items that will be reclassified to profit and loss | |||
| 4 | Income tax relating to items that will be reclassified to profit or loss | ||
| 5 | Total Other comprehensive income | 335.23 | 335.23 |